Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5463_Библиотеки_им_академика_М_И_Перельмана.pdf
18
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
antitumor activity against liver cancer (Sabry et al., 2021).
-
to deliver natural products. Alemi et al. (2018) prepared cationic PEGylated
-
to entrap resveratrol, a naturally occurring polyphenol having antitumor,
Ginkgo biloba
extract to increase oral bioavailability (Jin et al., 2013). Span 60, Span 80,
-
-
Niosomes in Delivery of Therapeutics and Biomedical Application
19
skin hydration, elasticity, thickness, roughness, and pigmentation. Lin et al.
antitumor properties and can be delivered transdermally by using niosomes
Hemoglobin can be transported by niosomes. Niosomes can also be used
20
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
also demonstrated higher hydration enhancement and improvements in
-
-
al., 2018).
1.2.3 NIOSOMES IN BIOMEDICAL APPLICATIONS
-tocopheryl PEG 1000
succinate, polyoxyethylene glycol 4000 stearate, sorbitan monostearate,
-
etheylenediaminetetraacetic acid used as a contrast agent and employed
Niosomes in Delivery of Therapeutics and Biomedical Application
21
N-palmitoylglucosamine, PEG4400,
paramagnetic drug as determined by MR imaging (Madhav and Saini,
in-vitro imaging studies revealed that these niosomes have considerable
-
nation has the potential to be used in dual-targeted glioma imaging (Ag
Seleci et al., 2021).
-
tions. Moreover, niosomes carrying inactivated vaccines have certain
advantages in pharmaceutical properties. Moreover, they can stimulate
vaccines and also preserve the encapsulated vaccine, lengthen the dura-
Pamornpathomkul and group prepared cationic niosomes by using Span
20, cholesterol, and cationic lipid (N
1
,N
1
-dimyristeroyloxyethyl-spermine)
mediated immunity, including serum immunoglobulin G (IgG) antibody
-
22
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
in-vivo and in-vitro study suggested that niosomal carbomer hydrogels
permeability, drug delivery to the brain is challenging, thereby restricting
selectively to the glioblastoma cells and prevent the usual brain tissue
carrier ligands alanine and glucopyranose and serum albumin complexed
ligands on niosomes boosted the cargo molecule uptake in the cultured
-
-
Niosomes in Delivery of Therapeutics and Biomedical Application
23
tumor-targeting and penetrating peptide (tLyp-1), and in-vitro experiments
-
core and superparamagnetic iron-oxide nanoparticles (Fe
x
O
y
-NPs) inside
uptake via an external magnetic manipulation and the results demonstrated
experiments using PEG-FA@Nio-Cur in breast cancer cells revealed
-
breast cancer therapy (Honarvari et al., 2022).
24
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
improved by condensing genetic material into various carriers (viral or
nonviral). Numerous cationic polymers, lipids, or peptides constitute the
delivery due to its less toxicity, stability, and enhanced solubility and
-
applications (Villate-Beitia et al., 2018). Niosomes can potentially be
-
Niosomes in Delivery of Therapeutics and Biomedical Application
25
FIGURE 1.4
Source
1.3 CONCLUSIONS AND FUTURE PROSPECTS
-
and nearly all pharmacological types. Niosomes can also be custom-made
-
26
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
that can yield unambiguously extraordinary results, particularly in sustained
KEYWORDS
• niosome
• nonionic surfactants
• therapeutics
• proteins and peptides
• gene and vaccine delivery
• biomedical application
REFERENCES
Glioma. Int. J. Mol. Sci. 2021, 22 (9), 4556.
RSC Adv. 2018, 8, 32621.
Pharm. Dev. Technol. 2017, 22 (3), 302–311.
Drug Dev. Ind. Pharm. 2012, 38,
84–92.
J.
Nanobiotechnol. 2018, 16, 28.
Niosomes in Delivery of Therapeutics and Biomedical Application
27
Hydrophobic Drugs. Toxicol. Res. 2018, 7, 771–778.
Int. J. Pharm.
2021, 598, 120380.
Drugs 1998, 56, 747–756.
Drug Deliv. 2017, 24, 414–421.
Sleep Med. Rev. 2005, 9, 25–39.
J. Pharm. Pharmacol. 1985, 37, 237–242.
J. Pharm.
Pharmacol. 1986, 38, 502–505.
Ellagic Acid and its Solubility Studies, J. Pharmaceut. Biomed. Anal. 2006, 40, 206–210.
Nature 1998, 392,
245–252.
J. Pharm. Bioal. Sci. 2013, 5, 318–325.
Biomaterials 2014, 35, 1643–1656.
Turk. J. Med. Sci. 2015,
45, 1403–1412.
Delivering Cancer Vaccines: Recent Advances. Nanomedicine 2020, 15 (15), 1527–1537.
Int. J. Pharm. 2013, 458,
287–295.
. Int. J. Pharm. 2013, 458 (2),
287–295.
in the Last Decade. J. Drug Deliv. Sci. Technol. 2020, 56, 101581.
Buckton, G. Interfacial Phenomena in Drug Delivery and Targeting.
1995
and Stability Evaluation. Colloids Surf. B. 2013, 111, 327–332.